EUROPE
In Europe, ZILBRYSQ® (zilucoplan) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Prescribing information Europe
ZILBRYSQ® SmPC (Sourced from www.ema.europa.eu)
USA
In the U.S. ZILBRYSQ® (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive.
Prescribing information USA
ZILBRYSQ® (zilucoplan) injection, for subcutaneous use
October 2023